A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
Sign Up to like & getrecommendations! Published in 2020 at "Internal Medicine"
DOI: 10.2169/internalmedicine.5893-20
Abstract: A durable response after the discontinuation of immune checkpoint-inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained a durable response after the discontinuation of nivolumab.… read more here.
Keywords: gastric cancer; durable response; response discontinuation; response ... See more keywords